Citation | Thomas, MG; De Rycker, M; Ajakane, M; Albrecht, S; Álvarez-Pedraglio, AI; Boesche, M; Brand, S; Campbell, L; Cantizani-Perez, J; Cleghorn, LAT; Copley, RCB; Crouch, SD; Daugan, A; Drewes, G; Ferrer, S; Ghidelli-Disse, S; Gonzalez, S; Gresham, SL; Hill, AP; Hindley, SJ; Lowe, RM; MacKenzie, CJ; MacLean, L; Manthri, S; Martin, F; Miguel-Siles, J; Nguyen, VL; Norval, S; Osuna-Cabello, M; Woodland, A; Patterson, S; Pena, I; Quesada-Campos, MT; Reid, IH; Revill, C; Riley, J; Ruiz-Gomez, JR; Shishikura, Y; Simeons, FRC; Smith, A; Smith, VC; Spinks, D; Stojanovski, L; Thomas, J; Thompson, S; Underwood, T; Gray, DW; Fiandor, JM; Gilbert, IH; Wyatt, PG; Read, KD; Miles, TJ Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis. J Med Chem62:1180-1202 (2019) [PubMed] Article |
---|
SMILES | COc1nc(N[C@H]2CC[C@@H](CC2)NS(=O)(=O)CCC(C)C)nc2[nH]nc(N3CCOC[C@H]3C)c12 |r,wU:6.5,wD:9.12,31.33,(12.05,-31.41,;10.72,-32.18,;10.72,-33.72,;12.06,-34.49,;12.06,-36.04,;13.4,-36.81,;14.73,-36.03,;14.71,-34.5,;16.05,-33.73,;17.39,-34.5,;17.38,-36.04,;16.05,-36.81,;18.72,-33.73,;20.05,-34.5,;20.81,-35.83,;19.28,-35.83,;21.39,-33.74,;22.72,-34.51,;24.06,-33.75,;25.39,-34.52,;24.06,-32.21,;10.72,-36.81,;9.39,-36.04,;7.92,-36.52,;7.01,-35.27,;7.91,-34.02,;7.43,-32.56,;8.45,-31.43,;7.97,-29.98,;6.47,-29.66,;5.45,-30.81,;5.93,-32.27,;4.91,-33.42,;9.38,-34.49,)| |